SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Impact of Practice-Level Telehealth on Quality Outcomes in Chronic Care
Practice-level telehealth quality outcomes remained stable for access and preventable hospitalizations among Medicare beneficiaries with chronic conditions during the COVID-19 pandemic. High-adopting primary care practices preserved care continuity while delivering modestly lower performance on s...
Large Language Models in Evidence-Based Medicine
Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa
African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...